#United States #Alpharetta #FDA #Acella Pharmaceuticals #NP Thyroid

Acella Pharmaceuticals Acknowledges FDA's Commitment to DTE Products

Acella Pharmaceuticals, the maker of NP Thyroid® (Thyroid Tablets, USP), expresses gratitude towards the U.S. Food and Drug Administration (FDA) for its recent announcement about the continued availability of desiccated thyroid extract (DTE) products. This notice comes as a vital reassurance for the approximately 1.5 million patients who depend on these medications while manufacturers navigate the Biologics License Application (BLA) process for animal-derived medicines that have yet to gain approval.

In a statement, Art Deas, the Chief Executive Officer of Alora Pharmaceuticals, the parent company of Acella Pharmaceuticals, highlighted the importance of the FDA’s clarification. He stated, "We appreciate the FDA's thoughtful consideration in providing this update as it supports patient access to these essential medicines while we progress toward FDA review." Deas also noted the company's commitment to maintaining high standards of quality and care for the patient community that relies on these treatments. Acella aims to ensure that DTE remains both accessible and affordable for users.

The FDA's recent communication also reaffirmed its responsibility to safeguard the health of patients currently using unapproved, animal-derived thyroid medications. The Agency has committed to a risk-based enforcement strategy regarding DTE products, promising to prioritize regulatory action against entities that fail to meet quality standards. Moreover, the FDA plans to release draft guidance detailing how DTE products may remain available on the market beyond August 2026, allowing manufacturers time to secure FDA approval of their products as biologics.

In a noteworthy development last September, Acella Pharmaceuticals, in collaboration with Neuvosyn Laboratories, announced positive outcomes from a Phase II clinical trial assessing North Star, an investigational DTE specifically designed for treating hypothyroidism. This trial marks a significant step as Neuvosyn aims to gain FDA approval under the BLA pathway for this new treatment option.

In his remarks, Deas emphasized that while DTE is categorized as a biological product, Acella intends to keep pricing reasonable, stating, "We are proud to support the Administration and FDA in their commitment to providing affordable medicines to hardworking Americans who need them." The implications of this commitment are profound, especially for patients managing hypothyroidism, a condition characterized by insufficient production of thyroid hormones.

These hormones are critical for multiple bodily functions, including metabolism regulation, energy generation, heart health, and cognitive function. Patients experiencing low thyroid hormone levels may struggle with symptoms such as fatigue, weight gain, depression, and cognitive difficulties. Thus, assuring the availability of reliable DTE products is essential for their health and quality of life.

For more detailed prescribing information about NP Thyroid®, including essential warnings, you can visit their official site at npthyroid.com/pi.

About Alora Pharmaceuticals

Alora Pharmaceuticals, LLC is the parent company of several specialty pharmaceutical and manufacturing enterprises, boasting production facilities located in Texas and Georgia. Headquartered in Alpharetta, GA, Alora comprises multiple organizations, including Avion Pharmaceuticals, Acella Pharmaceuticals, Osmotica Pharmaceuticals, Sovereign Pharmaceuticals, Trigen Laboratories, Neuvosyn Laboratories, Vertical Pharmaceuticals, and Glendale Pharmacy. Together, they are dedicated to meeting the pharmaceutical needs of patients and ensuring their access to essential medication.